Association between serotonergic antidepressant use during pregnancy and autism spectrum disorder in children

JAMA - Journal of the American Medical Association

Volumn 317, Issue 15, 2017, Pages 1544-1552

  Brown, Hilary K ^a,b,c   Ray, Joel G ^c,d,e   Wilton, Andrew S ^c   Lunsky, Yona ^b,c,f   Gomes, Tara ^b,c   Vigod, Simone N ^a,b,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; AUTISM; CANADA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; AUTISM SPECTRUM DISORDER; CHEMICALLY INDUCED; INCIDENCE; ONTARIO; PRENATAL EXPOSURE; PRESCHOOL CHILD; PROBABILITY; PROPENSITY SCORE; SIBLING; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIDEPRESSIVE AGENTS; AUTISM SPECTRUM DISORDER; CHILD, PRESCHOOL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INCIDENCE; MALE; ONTARIO; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROBABILITY; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SIBLINGS;

EID: 85021851750     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.3415     Document Type: Article

References (39)

1. Le Strat Y, Dubertret C, Le Foll B. Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord. 2011;135(1-3): 128-138.
2. Stein A, Pearson RM, Goodman SH, et al. Effects of perinatal mental disorders on the fetus and child. Lancet. 2014;384(9956): 1800-1819.
3. Howard LM, Molyneaux E, Dennis CL, et al. Non-psychotic mental disorders in the perinatal period. Lancet. 2014;384(9956): 1775-1788.
4. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity. JAMA. 2010;303(1): 47-53.
5. Andrade SE, Reichman ME, Mott K, et al. Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the US Food and Drug Administration's Mini-Sentinel program. Arch Womens Ment Health. 2016;19(6): 969-977.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
7. Harrington RA, Lee LC, Crum RM, et al. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 2013;6(3): 149-168.
8. Borue X, Chen J, Condron BG. Developmental effects of SSRIs. Int J Dev Neurosci. 2007;25(6): 341-347.
9. Brown HK, Hussain-Shamsy N, Lunsky Y, et al. The association between antental exposure to selective serotonin reuptake inhibitors and autism. J Clin Psychiatry. 2017;78(1): e48-e58.
10. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013; 369(25): 2406-2415.
11. Vigod SN, Gomes T, Wilton AS, et al. Antipsychotic drug use in pregnancy. BMJ. 2015; 350: h2298.
12. Ray JG, Schull MJ, Urquia ML, et al. Major radiodiagnostic imaging in pregnancy and the risk of childhood malignancy. PLoS Med. 2010;7(9): e1000337.
13. Burke JP, Jain A, YangW, et al. Does a claims diagnosis of autism mean a true case? Autism. 2014; 18(3): 321-330.
14. Frenette P, Dodds L, MacPherson K, et al. Factors affecting the age at diagnosis of autism spectrum disorders in Nova Scotia, Canada. Autism. 2013;17(2): 184-195.
15. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25): 3083-3107.
16. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario. Diabetes Care. 2002;25(3): 512-516.
17. Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54(6): 1423-1428.
18. Parkerson GR Jr, Harrell FE Jr, Hammond WE, Wang XQ. Characteristics of adult primary care patients as predictors of future health services charges. Med Care. 2001;39(11): 1170-1181.
19. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4): 512-522.
20. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60(7): 578-586.
21. Guertin JR, Rahme E, Dormuth CR, LeLorier J. Head to head comparison of the propensity score and the high-dimensional propensity score matchingmethods. BMC Med ResMethodol. 2016; 16: 22.
22. Enders D, Ohlmeier C, Garbe E. The potential of high-dimensional propensity scores in health services research: An exemplary study on the quality of care for elective percutaneous coronary interventions [published online January 16, 2017]. Health Serv Res. doi: 10.1111/1475-6773.12653
23. Schneeweiss S, EddingsW, Glynn RJ, et al. Variable selection for confounding adjustment in high-dimensional covariate spaces when analyzing healthcare databases. Epidemiology. 2017;28(2): 237-248.
24. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28): 3661-3679.
25. Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35(30): 5642-5655.
26. Donovan SJ, Susser E. Advent of sibling designs. Int J Epidemiol. 2011;40(2): 345-349.
27. Idring S,Magnusson C, Lundberg M, et al. Parental age and the risk of autism spectrum disorders. Int J Epidemiol. 2014;43(1): 107-115.
28. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11): 1104-1112.
29. Harrington RA, Lee LC, Crum RM, et al. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014; 133(5): e1241-e1248.
30. Gidaya NB, Lee BK, Burstyn I, et al. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. J Autism Dev Disord. 2014;44(10): 2558-2567.
31. Boukhris T, Sheehy O, Mottron L, Bérard A. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016;170(2): 117-124.
32. Sørensen MJ, Grønborg TK, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol. 2013;5: 449-459.
33. Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016;316(17): 1818-1819.
34. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders. Lancet. 2013;381(9875): 1371-1379.
35. Oberlander TF, Vigod SN. Developmental effects of prenatal selective serotonin reuptake inhibitor exposure in perspective. J AmAcad Child Adolesc Psychiatry. 2016;55(5): 351-352.
36. Jokiranta-Olkoniemi E, Cheslack-Postava K, Sucksdorff D, et al. Risk of psychiatric and neurodevelopmental disorders among siblings of probands with autism spectrum disorders. JAMA Psychiatry. 2016;73(6): 622-629.
37. Franklin JM, EddingsW, Glynn RJ, Schneeweiss S. Regularized regression versus the high-dimensional propensity score for confounding adjustment in secondary database analyses. Am J Epidemiol. 2015;182(7): 651-659.
38. Robins JM. Data, design, and background knowledge in etiologic inference. Epidemiology. 2001;12(3): 313-320.
39. Chaste P, LeboyerM. Autism risk factors: genes, environment, and gene-environment interactions. Dialogues Clin Neurosci. 2012;14(3): 281-292.